Day: July 23, 2025

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA, SOUTH AFRICA, NEW ZEALAND, JAPAN OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL  Reference is made to the stock exchange announcement made by Prosafe SE (“Prosafe” or the “Company“) on 18 July 2025 regarding the publication of a prospectus (the “Prospectus“) approved by the Norwegian Financial Supervisory Authority for, inter alia, the offering of up to 17,868,651 warrants (the “Warrants“) (the “Warrants Offering“). The subscription period for the Warrants Offering (the “Subscription Period“) commences today, 23 July 2025...

The Management Board of EfTEN Capital AS approved the updated version of the terms and conditions of EfTEN United Property Fund (hereinafter referred to as the Fund) by its decision of 19.06.2025. The Financial Supervision Authority approved the amendments to the Fund’s terms and conditions on 20.07.2025. As a result of the amendment to the Fund’s terms and conditions, the wording of the Fund’s investment restrictions was clarified in clause 3.11 of the terms and conditions. As a result of the clarification, the maximum restrictions on the level of the final investment made through another fund, i.e. the underlying fund, and directly into real estate have been outlined more clearly than before. No other changes to terms and conditions have been made. The amendment to the Fund’s terms and conditions does not change...

Approval based on INAVO120 data showing the Itovebi™ (inavolisib)-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone1 Up to 40% of ER-positive breast cancers have a PIK3CA mutation and are associated with poor prognosis; this approval helps address an urgent unmet need2-4 Itovebi is the first PI3K-targeted therapy to significantly extend survival, reinforcing the need for biomarker testing at diagnosis5Basel, 23 July 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has approved Itovebi™ (inavolisib), in combination with palbociclib (Ibrance®) and fulvestrant, for the treatment of adult patients with PIK3CA-mutated, oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced...

Elecsys pTau181 is the first In Vitro Diagnostic Regulation (IVDR) certified test to rule out Alzheimer’s associated amyloid pathology. The minimally invasive, blood-based test can serve as a rule out for Alzheimer’s pathology, reducing the need for confirmatory testing with a negative result. Data from clinical study supports use in primary care for people with varying signs of cognitive decline.Basel, 23 July 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today it has received CE Mark for its Elecsys® pTau181 test to measure phosphorylated Tau (pTau) 181 protein which is an indicator of amyloid pathology, a hallmark of Alzheimer’s disease. The test, which has been developed in collaboration with Eli Lilly and Company, can be used by clinicians in conjunction with other clinical information to rule out Alzheimer’s disease...

Equinor (OSE: EQNR, NYSE: EQNR) will on 24 July 2025 commence the third tranche of up to USD 1,265 million of the share buy-back programme for 2025, as announced in relation with the second quarter results 23 July 2025.  In this third tranche of the share buy-back programme for 2025, shares for up to USD 417.5 million will be purchased in the market, implying a total third tranche of up to USD 1,265 million including shares to be redeemed from the Norwegian State. The tranche will end no later than 27 October 2025.  Equinor announced at the Capital Market Update in February 2025 a share buy-back programme of up to USD 5 billion for 2025, including shares to be redeemed from the Norwegian State, in order to conclude the two-year programme for 2024 – 2025, announced in February 2024. The share buy-back programme will be subject to market...

Key information relating to the cash dividend to be paid by Equinor (OSE: EQNR, NYSE: EQNR) for the second quarter 2025.  Cash dividend amount: 0.37 Announced currency: USD Last day including rights: 12 November 2025 Ex-date Oslo Børs: 13 November 2025 Ex-date New York Stock Exchange: 14 November 2025 Record date: 14 November 2025 Payment date: 26 November 2025 Date of approval: 22 July 2025 Other information: The cash dividend per share in NOK will be communicated on 20 November 2025. This information is published in accordance with the requirements of the Euronext Oslo Børs Continuing Obligations and is subject to the disclosure requirements pursuant to Section 5-12 in the Norwegian Securities Trading Act. 

VANCOUVER, British Columbia, July 22, 2025 (GLOBE NEWSWIRE) — DMG Blockchain Solutions Inc. (TSX-V: DMGI) (OTCQB: DMGGF) (FRANKFURT: 6AX) (“DMG” or the “Company”), a vertically integrated blockchain and data center technology company, today announces that it has engaged a consultant to assess and help implement institutional-grade treasury management within the regulated custody platform operated by its wholly owned subsidiary, Systemic Trust Company (“STC”). This platform would serve both DMG and STC’s clients by offering custody services. DMG is also assessing additional capabilities intended to further enhance treasury value. Digital asset treasuries have recently gained prominence for their ability to generate net asset value (NAV) premiums through active management, in contrast to exchange-traded...